F-star Therapeutics, Inc.: Study Published in Nature Shows F-Star s STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled STING enhances cell death through regulation of reactive oxygen species and DNA damage demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma (HNSCC) and suggests that STING expression in the tumor is required for maximal therapeutic benefit. The studies described in this paper demonstrate that systemic administration of SB 11285, a novel STING agonist, in combination with radiation, enhances the antitumor effects in animal models of HNSCC. Furthermore, STING expression in the tumor can be used as a predictive biomarker and a combination of radiation with SB 11285 dem
Doeurm Kor market vendors queue to have their samples taken for Covid-19 testing on April 18. - The Phnom Penh Post/ANN PHNOM PENH, April 19 (Phnom Penh Post/ANN): The Ministry of Health has begun using the PANBIO COVID-19 Ag RAPID TEST DEVICE to check vendors at markets and other people in the vicinity who may have been infected by the virus.
Samdech Techo Voluntary Youth Doctor Association (TYDA), in collaboration with the ministry, said in statement: “We used this rapid test at the Neak Meas market [in Tuol Kork district] and it gave the results back in just 15 to 30 minutes.”
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Study Published in Nature Shows F-Star’s STING Agonist SB 11285 Enhances Preclinical Efficacy .
F-star Therapeutics, Inc.April 19, 2021 GMT
SB 11285 in Combination with Radiation is More Effective than Either as Monotherapy in a Murine Tumor Model
SB 11285 is a Second Generation STING Agonist Delivered Intravenously
CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021 (GLOBE NEWSWIRE) F-star Therapeutics, Inc. (NASDAQ: FSTX), a clinical-stage biopharmaceutical company dedicated to developing next generation bispecific immunotherapies to transform the lives of patients with cancer, today announced the publication of a new study, conducted by Yale University and F-star, of its second generation STING agonist, SB 11285, in the current issue of
Pharma Companies Seeking to Improve Health Outcomes With Innovative Products
- FN Media Group Presents Microsmallcap.com Market Commentary
News provided by
Share this article
Share this article
NEW YORK, April 8, 2021 /PRNewswire/ Conditions such as HIV, asthma, hepatitis, and severe migraines affect the quality of life of those living with these conditions. These conditions require patients to take preventive or control medication to avoid adverse developments due to the conditions. Pharmaceutical companies like
Valeo Pharma Inc. (CSE:VPH) (OTCQB:VPHIF), Pfizer (NYSE:PFE), AbbVie Inc. (NYSE:ABBV), and
Gilead Sciences (NASDAQ:GILD) have taken note of the challenges of managing these conditions and the potential of exacerbations and worse outcomes for people with poorly managed conditions. They have developed drugs and advanced care therapies that improve the management of these conditions. These developments in the pharmaceutical industry open up a potential market op
This One Quick Morning Habit Makes You A Better Leader, New Study Says forbes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from forbes.com Daily Mail and Mail on Sunday newspapers.